Nurse’s role in pharmacological pre-exposure prophylaxis of HIV infection

1. WHO. Estimated number of people (all ages) living with HIV. Published online 11.10.2021 https://www.who.int/data/gho/data/indicators/indicator-details/GHO/estimated-number-of-people--living-with-hiv (data dostępu: 12.10.2021) Search in Google Scholar

2. Zakład Epidemiologii Chorób Zakaźnych i Nadzoru Narodowego Instytutu Zdrowia Publicznego – Państwowego Zakładu Higieny. Zakażenia HIV i zachorowania na AIDS w Polsce w latach 1996-2020. http://wwwold.pzh.gov.pl/oldpage/epimeld/hiv_aids/index.htm (data dostępu: 12.10.2021). Search in Google Scholar

3. Krajowe Centrum ds. AIDS Agenda Ministra Zdrowia. Kampanie społeczne. https://aids.gov.pl/kampanie/kampanie-spoleczne/ (data dostępu: 12.10.2021). Search in Google Scholar

4. Szetela B, Gąsiorowski J, Łapiński Ł. Profilaktyka przedekspozycyjna zakażenia HIV. [W:] Parczewski M, Jabłonowska E, Witak-Jędra M, i wsp. Zasady opieki nad osobami zakażonymi HIV. Zalecenia polskiego towarzystwa naukowego AIDS 2021. Polskie Towarzystwo Naukowe AIDS Warszawa-Szczecin 2021: 38-42. Search in Google Scholar

5. Tsai CC, Follis K, Sabo A, et al. Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine. Science 1995; 270(5239): 1197-1199.10.1126/science.270.5239.11977502044 Search in Google Scholar

6. Cohen M, Kashuba A. Antiretroviral Therapy for Prevention of HIV Infection: New Clues From an Animal Model. PLoS Med. 2008 Feb; 5(2): e30.10.1371/journal.pmed.0050030222543118254655 Search in Google Scholar

7. Dobard C, Parikh U, Sharma S, et al. Complete protection against repeated vaginal simian HIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine [paper #46]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Quebec, Canada. Search in Google Scholar

8. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007 May 25; 2(5): e27.10.1371/journal.pctr.0020027187660117525796 Search in Google Scholar

9. Grohskopf L, Chillag K, Gyetadze R, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr 2013 Sep 1; 64(1): 79-86.10.1097/QAI.0b013e31828ece3323466649 Search in Google Scholar

10. Buchbinder S, Glidden D, Liu A, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis. 2014; 14(6): 468-475.10.1016/S1473-3099(14)70025-8413317124613084 Search in Google Scholar

11. Centers for Disease Control and Prevention: US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States–2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018. Search in Google Scholar

12. Sivay MV, Li M, Piwowar-Manning E, et al. HPTN 067/ADAPT Study Team. Characterization of HIV seroconverters in a TDF/FTC PrEP study: HPTN 067/ADAPT. J Acquir Immune Defic Syndr 2017; 75: 271-279.10.1097/QAI.0000000000001374547249328328548 Search in Google Scholar

13. Grulich AE, Guy R, Amin J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study, The Lancet HIV 2018; 5(11): e629-e637.10.1016/S2352-3018(18)30215-730343026 Search in Google Scholar

14. Jana S, Ray P, Roy S, et al. Successful integration of HIV pre-exposure prophylaxis into a community-based HIV prevention program for female sex workers in Kolkata, India. Int J STD AIDS. 2021 Jun; 32(7): 638-647.10.1177/0956462420983992809140433596735 Search in Google Scholar

15. Wilson C. Massive drop in London HIV rates may be due to internet drugs. New Scientist 2017 Jan 14(3108); https://www.newscientist.com/article/2117426-massive-drop-in-london-hiv-rates-may-be-due-to-internet-drugs/ (data dostępu: 12.10.2021). Search in Google Scholar

16. U.S. Food & Drug Administration. FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. 20.12.2021 https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention (data dostępu: 20.01.2022). Search in Google Scholar

17. Choi H, Suh J, Lee W, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV in men who have sex with men in South Korea: a mathematical modelling study Sci Rep. 2020; 10: 14609.10.1038/s41598-020-71565-y Search in Google Scholar

18. Alistar S, Grant P, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa BMC Med. 2014; 12: 46.10.1186/1741-7015-12-46 Search in Google Scholar

19. Suraratdecha C, Stuart R, Manopaiboon C, et al. Cost and cost-effectiveness analysis of pre-exposure prophylaxis among men who have sex with men in two hospitals in Thailand. J Int AIDS Soc. 2018 Jul; 21(Suppl Suppl 5): e25129.10.1002/jia2.25129605512930033559 Search in Google Scholar

20. Roberts A, Barnabas R, Abuna F, et al. The role of costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya. J Int AIDS Soc. 2019 Jul; 22(Suppl Suppl 4): e25296.10.1002/jia2.25296664307831328443 Search in Google Scholar

21. Cambiano V, Miners A, Dunn D, et al. Is Pre-Exposure Prophylaxis for HIV prevention cost-effective in men who have sex with men in the UK? A modelling and health economic evaluation Lancet Infect Dis. 2018 Jan; 18(1): 85-94.10.1016/S1473-3099(17)30540-6598803629054789 Search in Google Scholar

22. Bernard C, Brandeau M, Humphreys K, et al. Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Ann Intern Med. 2016 Jul 5;165(1):10-19.10.7326/M15-2634511818127110953 Search in Google Scholar

23. Nichols BE, Boucher CAB, van der Valk M, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016 Dec; 16(12): 1423-1429.10.1016/S1473-3099(16)30311-527665989 Search in Google Scholar

24. van de Vijver D, Richter A, Boucher C, et al. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Euro Surveill. 2019 Feb 14; 24(7): 1800398.10.2807/1560-7917.ES.2019.24.7.1800398638165930782266 Search in Google Scholar

25. Zhang L, Peng P, Wu Y, et.al. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. AIDS Behav. 2019 Feb; 23(2): 523-533.10.1007/s10461-018-2205-3631807429971734 Search in Google Scholar

26. Peebles K, Mugwanya K, Irungu E, et al. Low costs and opportunities for efficiency: a cost analysis of the first year of programmatic PrEP delivery in Kenya’s public sector. BMC Health Serv Res. 2021; 21: 823.10.1186/s12913-021-06832-3836592634399736 Search in Google Scholar

27. World Health Organisation. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. World Health Organization Geneva 2021. https://www.who.int/publications/i/item/9789240031593 (data dostępu: 17.02.2022). Search in Google Scholar

28. Wojciechowska AM (red.) Zapobieganie zakażeniom HIV, opieka nad ludźmi żyjącymi z HIV i chorymi na AIDS, Centrum Edukacji Medycznej; Warszawa 1996. Search in Google Scholar

29. Rogowska-Szadkowska D, Gąsiorowski J. HIV/AIDS dla pielęgniarek i położnych. Krajowe Centrum ds. –AIDS. Agenda Ministra Zdrowia. 2013 https://aids.gov.pl/publikacje/184/ (data dostępu: 17.02.2022). Search in Google Scholar

30. Borowiak E, Bebel G. Opieka pielęgniarska nad osobami z chorobami zakaźnymi. [W:] Talarska D, Zozulińska-Ziółkiewicz D. Pielęgniarstwo internistyczne. PZWL; Warszawa 2017. Search in Google Scholar

31. Minister Zdrowia- Krajowe Centrum ds. AIDS. Załącznik do uchwały nr 156/2016 Rady Ministrów z dnia 13 grudnia 2016 r. Harmonogram zadań realizowanych w ramach Krajowego Programu Zapobiegania Zakażeniom HIV i Zwalczania AIDS opracowany na lata 2017–2021. https://aids.gov.pl/wp-content/plugins/download-attachments/includes/download.php?id=4943 (data dostępu 11.11.2021). Search in Google Scholar

32. O’Byrne P, MacPherson P, Orser L, et al. PrEP-RN: Clinical Considerations and Protocols for Nurse-Led PrEP. J Assoc Nurses AIDS Care. 2019 May-Jun; 30(3): 301-311.10.1097/JNC.0000000000000075655124831008817 Search in Google Scholar

33. O’Byrne P, Orser L, Haines M. Active-Offer Nurse-Led PrEP (PrEP-RN) Referrals: Analysis of Uptake Rates and Reasons for Declining. AIDS Behav. 2020; 24: 1281-1289.10.1007/s10461-019-02745-9715635231773443 Search in Google Scholar

34. Kazakidis K, Kryczka T. Zaawansowana Praktyka Pielęgniarska jako panaceum systemu ochrony zdrowia w Polsce. Pielęgniarstwo XXI wieku 2021; 20(1): 50-57.10.2478/pielxxiw-2021-0002 Search in Google Scholar

35. O’Byrne P, Vandyk A, Orser L, et al. Nurse-led PrEP-RN clinic: a prospective cohort study exploring task-Shifting HIV prevention to public health nurses. BMJ Open. 2021 Jan 7; 11(1): e040817.10.1136/bmjopen-2020-040817779724333414144 Search in Google Scholar

36. Schmidt H-MA, McIver R, Houghton R, et al. Nurse-Led pre-exposure prophylaxis: a non-traditional model to provide HIV prevention in a resource-constrained, pragmatic clinical trial. Sex Health 2018; 15: 595-597.10.1071/SH1807630257752 Search in Google Scholar

37. Nelson LE, McMahon JM, Leblanc NM, et al. Advancing the case for nurse practitioner-based models to accelerate scale-up of HIV pre-exposure prophylaxis. Journal of Clinical Nursing 2019(28): 351-361.10.1111/jocn.1467530230068 Search in Google Scholar

38. Rabkin M, Lamb M, Osakwe ZT, et al. Nurse-led HIV services and quality of care at health facilities in Kenya, 2014-2016. Bull World Health Organ. 2017 May 1; 95(5): 353-361.10.2471/BLT.16.180646541882528479636 Search in Google Scholar

39. Charest M, Sharma M, Chris A, et al. (2021) Decentralizing PrEP delivery: Implementation and dissemination strategies to increase PrEP uptake among MSM in Toronto, Canada. PLoS ONE 16(3): e0248626.10.1371/journal.pone.0248626797152933735209 Search in Google Scholar

40. Zhang C, Mitchell W, Xue Y, et al. Understanding the role of nurse practitioners, physician assistants and other nursing staff in HIV pre-exposure prophylaxis care in the United States: a systematic review and meta-analysis. BMC Nurs. 2020; 19: 117.10.1186/s12912-020-00503-0772485633292201 Search in Google Scholar

41. Stockton JM. Assessment for sexually transmitted infections in men who have sex with men attending a nurse-run HIV preexposure prophylaxis clinic. J Am Assoc Nurse Pract. 2021; Feb 18; 33(12): 1290-1294.10.1097/JXX.000000000000056933625163 Search in Google Scholar